Glenn Steele Jr. M.D. Ph.D.

CIK: 0001269131

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (33.3%)

Position reduction

Option Exercises (M)2 (33.3%)

Derivative conversions

Awards (A)2 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PTCT

PTC THERAPEUTICS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

PTCT
PTC THERAPEUTICS, INC.
Sep 30, 2026
Exercise(M)
Direct
12K shares at avg. $11.23$135K
PTCT
PTC THERAPEUTICS, INC.
Sep 30, 2026
Sale(S)
Direct
12K shares at avg. $65.16$782K
PTCT
PTC THERAPEUTICS, INC.
Jan 2, 2026
Exercise(M)
Direct
12K shares at avg. $30.86$370K
PTCT
PTC THERAPEUTICS, INC.
Jan 2, 2026
Sale(S)
Direct
12K shares at avg. $76.35$916K
PTCT
PTC THERAPEUTICS, INC.
Jan 2, 2026
Award(A)
Direct
4K shares-
PTCT
PTC THERAPEUTICS, INC.
Jan 3, 2025
Award(A)
Direct
4K shares-

		Type	Shares	Price		Ownership
Sep 30, 2026	PTCT PTC THERAPEUTICS, INC.	Exercise(M)	12,000	$11.23	$134,760	Direct
Sep 30, 2026	PTCT PTC THERAPEUTICS, INC.	Sale(S)	12,000	$65.16	$781,920	Direct
Jan 2, 2026	PTCT PTC THERAPEUTICS, INC.	Exercise(M)	12,000	$30.86	$370,320	Direct
Jan 2, 2026	PTCT PTC THERAPEUTICS, INC.	Sale(S)	12,000	$76.35	$916,200	Direct
Jan 2, 2026	PTCT PTC THERAPEUTICS, INC.	Award(A)	4,000	-	$0	Direct
Jan 3, 2025	PTCT PTC THERAPEUTICS, INC.	Award(A)	4,000	-	$0	Direct

1-6 of 6 transactions

About STEELE GLENN JR MD PHD

STEELE GLENN JR MD PHD (SEC CIK 0001269131) files insider reports with the SEC as Director of PTC THERAPEUTICS, INC. (PTCT).

Signal8 holds 3 ownership filings by STEELE GLENN JR MD PHD, all Form 4s, filed between Jan 7, 2025 and Oct 2, 2026. Those filings report 6 transactions, from Jan 3, 2025 to Sep 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on STEELE GLENN JR MD PHD's filings is in WARREN, NJ.

Recent filings by STEELE GLENN JR MD PHD

Sep 30, 2026: Option exercise of PTCT shares (Form 4, code M).
Sep 30, 2026: Open-market sale of PTCT shares (Form 4, code S).
Jan 2, 2026: Option exercise of PTCT shares (Form 4, code M).
Jan 2, 2026: Open-market sale of PTCT shares (Form 4, code S).
Jan 2, 2026: Grant or award of PTCT shares (Form 4, code A).

Other insiders filing for PTC THERAPEUTICS, INC. (PTCT)

SCHMERTZLER MICHAEL, Director
Boulding Mark Elliott, EXEC. VP AND CLO
Klein Matthew B., CHIEF EXECUTIVE OFFICER
Sollie-Zetlmayer Hege Elisabeth, Director
Gravier Pierre, CHIEF FINANCIAL OFFICER
Smith Mary L., Director

How to read Form 4 transaction codes